Founder effect in the Horn of Africa for an insulin receptor mutation that may impair receptor recycling by Raffan, E. et al.
ARTICLE
Founder effect in the Horn of Africa for an insulin receptor
mutation that may impair receptor recycling
E. Raffan & M. A. Soos & N. Rocha & A. Tuthill & A. R. Thomsen & C. S. Hyden &
J. W. Gregory & P. Hindmarsh & M. Dattani & E. Cochran & J. Al Kaabi & P. Gorden &
I. Barroso & N. Morling & S. O’Rahilly & R. K. Semple
Received: 20 September 2010 /Accepted: 7 January 2011 /Published online: 12 February 2011
# The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract
Aims/hypothesis Genetic insulin receptoropathies are a rare
cause of severe insulin resistance. We identified the
Ile119Met missense mutation in the insulin receptor INSR
gene, previously reported in a Yemeni kindred, in four
unrelated patients with Somali ancestry. We aimed to
investigate a possible genetic founder effect, and to study
the mechanism of loss of function of the mutant receptor.
Methods Biochemical profiling and DNA haplotype analysis
of affected patients were performed. Insulin receptor expres-
sion in lymphoblastoid cells from a homozygous p.Ile119Met
INSR patient, and in cells heterologously expressing the
mutant receptor, was examined. Insulin binding, insulin-
stimulated receptor autophosphorylation, and cooperativity
andpHdependencyofinsulindissociationwerealsoassessed.
Results All patients had biochemical profiles pathogno-
monic of insulin receptoropathy, while haplotype analysis
revealed the putative shared region around the INSR mutant
to be no larger than 28 kb. An increased insulin proreceptor
to β subunit ratio was seen in patient-derived cells. Steady
state insulin binding and insulin-stimulated autophosphor-
ylation of the mutant receptor was normal; however it
exhibited decreased insulin dissociation rates with pre-
served cooperativity, a difference accentuated at low pH.
Conclusions/interpretation The p.Ile119Met INSR appears
to have arisen around the Horn of Africa, and should be
sought first in severely insulin resistant patients with
ancestry from this region. Despite collectively compelling
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Introduction
Insulin resistance is a common consequence of obesity, and
is frequently a prelude to frank type 2 diabetes [1].
Uncommonly, severe insulin resistance is seen in lean
people, often presenting with features of ovarian hyper-
androgenism and ovulatory dysfunction in women before
hyperglycaemia ensues [2, 3]. In most cases, such severe
insulin resistance is believed to have a genetic basis, and
around 10–20% of such patients have loss-of-function
mutations in the insulin receptor INSR gene [4].
Since the first description of INSR mutations in patients
with severe insulin resistance in 1988 [5, 6], nearly 100
allelic variants have been described [4], and many of these
have been characterised in vitro. Such studies were the
basis of the classification by Taylor and colleagues in 1992
of pathogenic INSR mutations into five classes, defined by
defects in receptor expression, trafficking to the cell
surface, insulin binding, signal transduction or receptor
recycling, respectively [7]. Although many mutant recep-
tors with defective trafficking and/or insulin binding and/or
signal transduction have been described, mutations pre-
dominantly affecting receptor endocytosis or recycling are
rare. The best studied examples are the Lys460Glu [8] and
Ser462Asn [9] mutations, which perturb a critical hinge
region of the insulin binding domain of the receptor [10],
leading to impaired dissociation of bound insulin in acidic
conditions [8, 9], and the Arg252Cys mutation, which
impairs receptor endocytosis [11].
Genetic defects in the insulin receptor produce a clinical
spectrum of abnormality. Biallelic mutations most com-
monly produce Donohue or Rabson–Mendenhall syn-
dromes, disorders with marked impairment of linear
growth, soft tissue overgrowth and extreme metabolic
derangements that lead to mortality between infancy and
early adulthood [2, 3]. The less severe end of the spectrum
comprises severe insulin resistance usually presenting
peripubertally in females with hyperandrogenism, oligome-
norrhoea and acanthosis nigricans [2, 3]. Heterozygous
mutations in the intracellular domain of the insulin receptor
are most commonly found in this setting, transmitting disease
with autosomal dominant inheritance, but a minority of such
patients have milder, biallelic mutations in the extracellular
domain with autosomal recessive inheritance [4].
One reported cause of such milder, autosomal reces-
sive disease is the p.Ile119Met mutation in the alpha
subunit, reported in a single Yemeni kindred [12, 13].
Although a case was made for the pathogenicity of the
mutant based on a two point logarithm (base 10) of the
odds (LOD) score derived from this single family [12], no
functional studies of the mutant in vitro or ex vivo have
been reported. Since the index report we have identified
four unrelated patients of Somali ancestry with the same
INSR mutation, which did not occur in any other patients
with severe insulin resistance. We thus set out to assess the
mechanism of loss of function of the Ile119Met mutant
insulin receptor, and, given the close geographical proximity
of Somalia and the Yemen in the region of the Horn of Africa,
to investigate a likely geographic founder effect for this
mutation.
Methods
Patients All patients were studied with informed consent in
line with procedures approved either by the local research
ethics committee in Cambridge, UK, or the institutional
review board of the National Institute of Diabetic and
Digestive and Kidney Diseases. Rabson–Mendenhall syn-
drome was defined by prepubertal presentation withclassical
syndromic features and survival beyond 3 years old. Type A
insulin resistance denotes severe hyperinsulinaemia, acan-
thosis nigricans and hyperandrogenism, presenting post- or
peri-pubertally in girls.
Biochemical assays Blood was drawn after a 12 h fast, and
plasma stored at −20°C. Insulin, leptin and adiponectin
were assayed using previously described dissociation-
enhanced lanthanide fluorescence immunoassays [14]. All
other assays were undertaken in accredited diagnostic
laboratories of referring hospitals.
Molecular genetic studies Genomic DNA was extracted
from peripheral blood leucocytes before PCR amplification
of all exons of the INSR and 50 bp of their flanking
sequences. Primer sequences are available on request. PCR
products were purified using Agencourt CleanSEQ reagents
(Agencourt Bioscience Corporation, Beverly, MA, USA)
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sequencer (Applied Biosystems, Warrington, UK). Se-
quence analysis was performed using Softgenetics Mutation
Surveyor (State College, PA, USA).
DNA from 100 unrelated, healthy Somalian immigrants to
Denmark was typed for the INSR Ile119Met variant using
PCR and single base extension (SBE) [15]. Exon 2 of INSR
was amplified by PCR as described above and treated with
ExoSAP-IT (USB, Cleveland, OH, USA) to remove single
stranded nucleotides and excess dNTPs. The Ile119Met
mutation was typed using SBE with the SNapShot kit (Applied
Biosystems). The following primer was used for the SBE (the
single nucleotide polymorphisms [SNPs] are underlined):
Ile119Met (reverse): GAGCTCATTGTTCTTCTC-G/C. The
SBE reaction was performed in triplex. Excess ddNTPS
were removed with shrimp alkaline phosphatase before
samples were run on an ABI Prism ABI3130 genetic
analyser (Applied Biosystems). Allele determination was
undertaken using Genescan 3.7 and Genotyper 3.7
software (Applied Biosystems) [15]. DNA from two
patients was applied as positive control and both were
homozygous for the Ile119Met mutation. INSR sequence data
from 179 individuals of different ethnic origins in the 1000
Genomes Project pilot 1 data release (April 2009, 100328;
ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/pilot_data/release/
2010_03/pilot1/README_SRP000031.2010_03_snps)a n d
exome-wide sequencing data from 354 Europid individuals
(I. Barroso, unpublished data) were additionally interrogated
for the presence of the p.Ile119Met and p.Arg1039X
mutations.
Patients were genotyped for three microsatellite markers
flanking INSR (D19S916, D19S873, D19S216); an unan-
notated microsatellite consisting of a tandem AC repeat
within intron 1 of the insulin receptor gene (position
19:7269388-7269437, bounded by rs67146219 and
rs711177190, Ensembl assembly GRCh37, named 25AC
in Table 2); and SNPs in introns 1 and 2 chosen for having
a minor allele frequency ≥40% in the Yoruba population in
Ibadan, Nigeria (YRI) (the International HapMap Project
[16] accessed 17 May 2010) (rs7254487, rs6210958,
rs7248939, rs11671297, rs4804433, rs3852876, rs57930737,
and rs4499341). Microsatellites were amplified using GoTaq
Green chemistry (Promega, Madison, WI, USA) according to
the manufacturer’s instructions using a FAM fluorescent tag
on the reverse primer. Products were diluted and mixed with
GeneScan 500LIZ Size Standard (Applied Biosystems) and
run on an ABI 3730 DNA Analyser (Applied Biosystems).
Allele determination was undertaken using GeneMapper
software (Applied Biosystems). For SNP genotyping, DNA
wasamplifiedusingGoTaqGreenchemistry,sequencedusing
a BigDye Terminator v3.1 Cycle Sequencing kit (Applied
Biosystems), run on the ABI 3730 DNA Analyser, and
genotype calls were made using Sequencher software (Gene
Codes Corporation, Ann Arbor, MI, USA). Primer sequences
are available upon request.
Structural modelling The effect of the Ile119Met mutation
was assessed structurally using SWISS-MODEL and the
Swiss-PdbViewer [17]( www.expasy.org/spdbv/). The pdb
file used for modelling was 2hr7 [18].
Lymphoblastoid cell culture Epstein–Barr virus transformed
lymphoblastoid (EBVL) cell lines were generated from
patient and control whole blood by the European Collection
of Cell Cultures (Porton Down, UK) and maintained in
RPMI-1640 medium (Sigma-Aldrich, St Louis, MO, USA)
supplemented with 10% (wt/vol.) fetal bovine serum (FBS),
2 mmol/l L-glutamine and 100 U/l penicillin and 100 μg/ml
streptomycin (all from Sigma-Aldrich).
Site-directed mutagenesis and expression of mutant receptor
in vitro Point mutations were introduced using the Quik-
ChangeXL Site-Directed Mutagenesis Kit (Stratagene, La
Jolla, CA, USA) according to the manufacturer’s instruc-
tions. All constructs were in the pRc.CMV expression
vector (Invitrogen, Leek, the Netherlands), and the resulting
mutations were verified by sequencing. For functional
studies, Chinese hamster ovary (CHO) cells maintained at
37°C in Nutrient F-12 Ham’s medium (Sigma-Aldrich,
Irvine, UK) supplemented with 10% (wt/vol.) fetal calf
serum, 1,000 U/l penicillin, 0.1 g/l streptomycin, and
2 mmol/l L-glutamine were transfected using FuGENE
(Roche) as transfection reagent. All experiments were
performed between 36 and 48 h after transfection.
Insulin-induced receptor autophosphorylation Transfected
cells were serum-starved for 6 h, and then stimulated with
100 nmol/l insulin for 5 min at 37°C. Following
stimulation, cells were washed with ice cold PBS and
solubilised in 5 μl lysis buffer/1 cm
2 confluent cells. Lysis
buffer contained 50 mmol/l Hepes, 150 mmol/l NaCl,
30 mmol/l NaF, 10 mmol/l Na4P2O7, 1 mmol/l Na2VO4,
1% (vol./vol.) Triton X100, 10 mmol/l EDTA and 1 tablet
of protease inhibitor mini complete cocktail (Roche,
Mannheim, Germany) per 7 ml buffer. Protein concentra-
tion was quantified using a Bio-Rad DC protein assay
(Bio-Rad Laboratories, Hercules, CA, USA). Cell lysates
were electrophoresed under reducing, denaturing condi-
tions in 8% (wt/vol.) polyacrylamide gels (SDS-PAGE).
Proteins were transferred to Immobilon-P polyvinylidene
fluoride membranes (Millipore, Bedford, MA, USA), and
membranes were probed with the rabbit anti-insulin
receptor polyclonal antibody followed by horseradish
peroxidase-conjugated secondary antibody. Antibody
binding was assessed using enhanced chemiluminescence
(Amersham Pharmacia Biotech, Little Chalfont, UK) and
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Insulin binding assays Insulin binding was determined by
washing transiently-transfected CHO cells in 24-well plates
twice with PBS prior to incubation with [
125I]insulin (3×
10
−11–4×10
−11 mol/l) together with unlabelled insulin for
6 h at 4°C in binding buffer (100 mmol/l HEPES (pH 7.8),
120 mmol/l NaCl, 1 mmol/l EDTA, 15 mmol/l sodium
acetate, 1.2 mmol/l MgSO4, 10 mmol/l glucose, and 1%
[wt/vol.] BSA). Cells were then washed twice with ice cold
PBS and solubilised in 0.03% (wt/vol.) sodium dodecyl
sulfate for determination of cell-bound radioactivity in a γ-
counter (1282 Compugamma CS Universal γ-Counter,
LKB Wallac, Turku, Finland). Nonspecific binding deter-
mined in the presence of 1 μmol/l unlabelled insulin was
subtracted and results were standardised to that bound by
the wild-type receptor.
Insulin dissociation assays For insulin dissociation studies,
60,000 CHO cells were seeded per well of five 24 well plates
and transfected with 400 ng of the appropriate plasmid using
polyethylimine, 12 h after seeding, before dissociation
studies, when cells were at 70–90% confluence.
To assess the insulin dissociation rate from heterologously
expressed receptors, plates were placed on ice, before
aspiration of medium and washing twice with PBS. 150 μl
of binding buffer (120 mmol/l NaCl, 2.5 mmol/l KCl,
15 mmol/l Na acetate, 1 mmol/l EDTA, 1.2 mmol/l MgSO4,
10 mmol/l glucose, 1% (wt/vol). BSA, 50 mmol/l HEPES,
pH 7.8) was added to all wells, followed by 100 μl binding
buffer with or without cold insulin as appropriate. To the
relevant wells 50 μlo f
125I-labelled insulin (10–15,000 cpm)
was then added before incubation at 4°C with shaking for 4–
6 h. Plates were then put on ice, buffer was aspirated and
cells were washed twice with ice cold PBS. Cells in one
plate were then solubilised in 200 μl 0.03% (wt/vol.) SDS
for 30 min at room temperature before counting in a γ-
counter to determine insulin binding prior to dissociation.
For cooperativity studies, 250 μl of dissociation buffer
(120 mmol/l NaCl, 4.5 mmol/l KCl, 1 mmol/l EDTA,
1.2 mmol/l MgSO4, 10 mmol/l glucose, 1% [wt/vol.] BSA,
and 50 mmol/l HEPES, pH 7.8) was added to each well
with additional cold insulin to final concentrations of 0, 0.1
and 10 μmol/l as appropriate, prior to incubation for 5 min
at 4°C. Medium was then removed for counting before
washing of cells with ice cold PBS and solubilisation and
counting as before. For studies of the pH dependency of
insulin dissociation buffers containing 120 mmol/l NaCl,
4.5 mmol/l KCl, 1 mmol/l EDTA, 1.2 mmol/l MgSO4,
10 mmol/l glucose, 1% (wt/vol.) BSA, and either
100 mmol/l MES (for pH 5.5), ACES (for pH 6.2), HEPES
(for pH 7.0) or TAPS (for pH 7.8) were used, and no
additional cold insulin was added during dissociation. All
chemical reagents were purchased from Sigma unless
otherwise indicated.
Statistics Paired t tests were used to compare insulin
dissociation at each pH tested. In cooperativity studies,
two way ANOVAwas used to compare insulin binding over
time in the differently transfected cells and at different
insulin concentrations.
Results
Case histories Clinical and biochemical features of all
patients studied are summarised in Table 1, and more
detailed clinical summaries are provided as Electronic
Supplementary Material (ESM). Although only 10–20%
of postpubertal patients with severe insulin resistance
harbour insulin receptor mutations [4], all patients we
describe had strikingly elevated levels of serum adiponec-
tin, SHBG and/or IGFBP1, where measured, as well as a
normal lipid profile, a pattern which we have found to be
pathognomonic of insulin receptoropathy [19, 20]. Indeed,
the adiponectin level in patient 4, at 98 mg/l, is the highest
level our laboratory has recorded, and is nearly three times
higher than the highest value recorded in 900 healthy
Europid controls. Thus, on biochemical grounds alone,
there is compelling evidence that all five patients have
insulin receptoropathy [7].
Genetic studies Patients 1, 2, 3 and 4 were all homozygotes
for the INSR p.Ile119Met (c.576C>G) mutation (numbered
according to the sequence of the mature receptor; Fig. 1a).
Patient 5 was a compound heterozygote for the p.Ile119Met
and p.Arg1039X (c.33342C>T) mutations, the p.Ile119Met
variant having been inherited from his Somali father, and
the p.Arg1039X from his French mother. p.Arg1039X,
although not previously described, was not detected in
more than 400 Europid control genomes and exomes.
Cosegregation between homozygosity for INSR Ile119Met
and severe insulin resistance has previously been reported
in the family of Patient 1. No family members were
available for study for patients 2, 3, and 4, while patient 5
had no siblings. Ile119 is a strongly conserved residue in
the L1 domain of the alpha subunit of the insulin receptor,
where it lies in the central beta sheet of the fifth strand, its
side chain directed inwards towards the core of the L1
domain, and substitution for methionine is predicted to alter
packing within the barrel (Fig. 1b, c).
To determine whether INSR Ile119Met is a common
variant in the Somali population we screened 100 unrelated
Somali controls, but failed to identify any mutant alleles,
giving 95% confidence that the mean allele frequency in the
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Diabetologia (2011) 54:1057–1065 1061Somali population is ≤1.5% [21]. We then undertook
further studies in affected patients to seek an informative
haplotype including microsatellites and SNPs (Table 2).
Despite screening a wide range of microsatellites and SNPs
with mean allele frequencies reported to be ≥40% in the
Yoruba population, it was not possible definitively to
identify a shared haplotype. However, it was possible to
establish an upper size limit of 28 kb for the putative shared
haplotype, suggesting that the common ancestry of our
patients is ancient.
Expression and function of the Ile119Met INSR Expression
of the Ile119Met INSR was first determined in EBVL cells
from Patient 1. Compared with controls, expression of the
mature β subunit of the receptor was normal; however there
was a consistent slight increase in the proreceptor to mature
β subunit ratio (Fig. 2a). On heterologous expression of the
mutant receptor in CHO cells, a similar pattern was often,
though not invariably, seen, suggesting mildly impaired
proreceptor processing (Fig. 2b). Despite this, insulin-
induced receptor autophosphorylation was grossly normal
(Fig. 2b).
Insulin binding by the Ile119Met INSR Steady state insulin
binding by both EBVLs from one patient with homozygous
p.Ile119Met INSR mutations (Fig. 3a), and by CHO cells
heterologously expressing the mutant receptor (Fig. 3b–d),
was normal, in keeping with the normal receptor autophos-
phorylation. However, in view of the convincing receptor-
opathy phenotype of all patients, we elected to investigate
insulin binding by the mutant receptor in more detail. It is
well established that increasing the level of receptor
occupancy by addition of unlabelled insulin alters the
insulin dissociation rate [22–24]. With a wild type receptor,
addition of insulin at concentrations up to 5,000 ng/ml
(861 nmol/l) accelerates the rate at which bound
125I-insulin
dissociates from the receptor—a phenomenon termed ‘nega-
tive cooperativity’—while addition of insulin at concentra-
tions up to 50,000 ng/ml (8,610 nmol/l) reduces this—termed
‘positive cooperativity’. As Ile119 is near the interface
between adjacent α subunits, it seemed possible that it might
play a role in mediating the cooperative interactions between
insulin binding sites. However, although insulin dissociation
rates were indeed slower for the mutant receptor than the wild
type receptor in all conditions, both types of cooperativity
were preserved (Fig. 4).
After insulin binding to its receptor,the ligand–receptor
complex is internalised and routed to acidified endosomes,
where it may either be degraded or recycled to the plasma
membrane after insulin dissociation. Thus, specific impair-
ment of insulin dissociation in acidic conditions would be
predicted to impair receptor recycling, potentially signifi-
cantly reducing cell surface insulin receptor expression in
the face of tonic insulin action. Such a phenomenon has
been described for the Lys460Glu and Ser462Asn mutant
insulin receptors [8, 9]. In closely similar studies, the mild
reduction in dissociation rate of insulin from the Ile119Met
mutant receptor was also found to be increased at low pH
(Fig. 5), although the magnitude of this effect was smaller
than reported for the Lys460Glu and Ser462Asn mutants.
Human            103 ELGLYNLMNITRGSVRIEKNNELCYLATIDW 134
Mouse               ELGLYNLMNITRGSVRIEKNNELCYLATIDW 
Danio rerio EIGLHSLMNITRGAVRVEKNPDLCYLSTLDW 
Xenopus DIGLYSLTNILNGAVRIERNQELCHISTIDW 
Aedes aegypti EIGLISLMDITRGGVRIEKNPKLCFANTIDW 
Drosophila DLGLHKLRSITRGGVRIEKNHKLCYDRTIDW 
C. elegans EIGLDKLSVIRNGGVRIIDNRKLCYTKTIDW 
::** .* * .*.**:  * .**. *:**
a
b
c
WT
P1
P2
TRGSVRIEKNN
TRGSVRMEKNN
123 113
L2 L2
L2
L1
L1
Met119
Ile119
Fig. 1 Identification and location of the Ile119Met INSR mutation.
a Genomic DNA sequence of Patient 2, showing homozygous
INSR c.576C>G mutation with resulting p.Ile119Met substitution.
b Phylogenetic conservation of Ile119. c Ile119 (red) and Met119
(yellow) represented on different alpha subunits in a detail of the
crystal structure of the insulin receptor alpha subunit dimer (L1 and
L2 are EGF-like domains), with close-up views down the barrel of the
L1 domain showing the modest change caused by substitution of
Ile119 by methionine. WT, wild type
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Over the past 22 years, since the index reports of loss-of-
function mutations in the human insulin receptor associated
with extreme insulin resistance, more than 100 pathogenic
mutations have been described [4]. Relatively few recurring
mutations have been reported, although in our own practice
we have identified the Pro1178Leu variant in six unrelated
Europid patients, adding to the index Japanese report, and the
Pro193Leu variant in unrelated Saudi and Afghan families.
No geographical founder effects have been demonstrated.
Thus our finding of the p.Ile119Met variant in five unrelated
patients, all of whom trace ancestry to Somalia or the Yemen,
is striking. Indeed, this mutation has been found in all the
Somali patients referred to us with extreme insulin resistance,
but in no other patient. On these grounds alone, we believe
this represents a founder effect in the region of the Horn of
Africa. Although we sought to corroborate this by comparing
the haplotype around the mutation between patients, lack of
variabilityinmarkersaroundthemutationlocusmeantthatwe
could only establish an upper size limit of 28 kb for the
putative ancestralhaplotype,suggestingthatanysuchfounder
effect must be ancient.
The previous report of the p.Ile119Met mutation associ-
ated with extreme insulin resistance included determination
of a LOD score of between 3.4 and 4.6, depending on the
allele frequency in the population. Our demonstration here,
that none of 100 Somali controls carries the mutation,
suggests that the higher end of this range is appropriate,
providing strong genetic evidence for the pathogenicity of
the mutation. We have now determined that patients
homozygous for the Ile119Met variant not only have
extreme insulin resistance, but also have a biochemical
phenotype—extreme hyperinsulinaemia, high adiponectin,
SHBG and IGFBP1, and normal lipid profile—which we
have found to be pathognomonic for insulin receptor
dysfunction [19, 20]. We thus believe that the collective
clinical, genetic and biochemical evidence that the Ile119-
Met INSR allele severely impairs insulin receptor function
in vivo is incontrovertible.
Nevertheless, there have been no reports to date of in
vitro characterisation of the Ile119Met mutant receptor. We
now report such studies, and surprisingly the in vitro defect
is very subtle. Most alpha subunit mutations that have been
studied to date either impair proreceptor processing and thus
cell surface expression of mature receptors, or severely affect
insulin binding to the receptor [4, 7]. However, insulin
binding in both primary cells from an Ile119Met INSR
homozygous patient, and in cells heterologously expressing
Pro-receptor
β subunit
CC C C C C
P1
CC C
DS2 RMS DS1
a
b
Pro-receptor
β subunit  
Phospho- 
β subunit  
Insulin (100 nmol/l) + ++ - - -
Mock I119M WT
Fig. 2 Expression and insulin-induced autophosphorylation of the
Ile119Met insulin receptor. a Expression of the insulin receptor in
lymphoblastoid cells from Patient 1 (P1), from healthy controls (C), or
from patients with Donohue syndrome (DS): DS1 is a compound
heterozygote for p.Cys274Tyr/p.Arg1174Trp INSR mutations; DS2 is
a compound heterozygote for fs.108(109X)/p.Gln272X INSR muta-
tions, or Rabson–Mendenhall syndrome (RMS), with compound
heterozygous p.His209Arg/p.Gly359Ser INSR mutations. Cell lysates
were immunoprecipitated with 83-14 anti α subunit antibody prior to
immunoblotting with anti β subunit antibody. b Heterologous over-
expression of wild-type (WT) or mutant INSR in CHO cells, and
receptor autophosphorylation in response to insulin. IP: 83-14 mAb;
Blot: anti-InsR b subunit (Santa Cruz)
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Fig. 3 Insulin binding by the Ile119Met (I119M) insulin receptor.
a Insulin and IGF-1 binding by lymphoblastoid cells from Patient 1
and a wild-type (WT) control and (b) Insulin binding by wild-type and
Ile119Met mutant insulin receptor after overexpression in CHO cells
(insulin: black circles, wild-type; black squares, Ile119Met; white
circles, mock. IGF-1: upwards triangles, WT; downwards triangles,
Ile119Met.) c Maximum steady state insulin binding by WT and
Ile119Met mutant insulin receptors. d IC50 for insulin binding for
wild-type and Ile119Met mutant insulin receptors
Diabetologia (2011) 54:1057–1065 1063the mutant receptor, showed normal steady state insulin
binding, although there was very subtle evidence of aberrant
processing of the proreceptor in both situations, and insulin-
stimulated receptor autophosphorylation was normal.
Study of the Lys460Glu and Ser462Asn mutant recep-
tors has previously shown that some α subunit mutations
result in impaired cooperativity in insulin binding, or in
altered pH-dependence of insulin dissociation [8, 9]. In the
case of the Ile119Met mutant, insulin dissociation was
slightly slower at baseline than that from wild-type
receptor; however both positive and negative cooperativity
were preserved. The impaired dissociation rate was accen-
tuated, however, under acidic conditions. This would be
predicted to favour degradation of insulin-receptor com-
plexes in acidified endosomes after internalisation in vivo,
and reduce the amount of receptor recycling to the cell
surface, which requires insulin dissociation. Substitution of
Ile119 by methionine is predicted to alter the packing
within the barrel of the L1 domain only modestly,
potentially leading to compensation in the sheet structure
itself. However Ile119 is neighboured by Arg118 and
Glu120, both of which have recently been shown to play
a key role in creating so-called site 1 for insulin binding to
the receptor through formation of a charge compensating
cluster with residues Glu698 and Arg702from the C
terminal alpha helix of the alpha subunit [25]. In this key
structural context it is plausible that substitution of Ile119
for methionine may perturb some aspect of the dynamic
interaction ofthe alpha subunit withinsulin.Nevertheless, our
functional studies are not comprehensive, and it remains
possible that a further, unstudied aspect of insulin receptor
function is selectively affected by the Ile119Met mutation, or
that this mutation may have a greater deleterious effect in the
context of the longer ‘B’ isoform of the insulin receptor that
includesthesmallexon11.Inparticular,itwouldbeofinterest
to study surface distribution of the insulin receptor and
insulin-dependent receptorinternalisation,processes thathave
beenshowntobeimpairedbyanotheralphasubunitmutation,
albeit one affecting the cysteine-rich domain rather than the
L1 domain [11].
The current wealth of genome-wide association studies
revealing statistical associations between disease traits
and common genetic variants has led to keen interest in
trying to assign specific functional consequences to each
such variant. In this context it is sobering to reflect that,
despite the compelling case for defective insulin receptor
function in the patients studied, and the wealth of
understanding of insulin receptor function, it has proved
extremely difficult to demonstrate a defect in insulin
signalling in vitro commensurate with the clinical
severity of the phenotype. This emphasizes the chal-
lenges that lie ahead in translating pure genetic associ-
ations into cellular disease mechanism.
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125I-insulin dissociation rates and cooperativity of insulin
binding for the Ile119Met insulin receptor. Insulin dissociation rate,
showing positive and negative cooperativity for (a) wild-type and
(b) Ile119Met insulin receptor overexpressed in CHO cells. c Reduced
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Fig. 5 Effect of pH on dissociation of
125I-insulin from the Ile119Met
and wild-type insulin receptors. pH dependency of insulin dissociation
is shown for wild-type and mutant insulin receptors overexpressed in
CHO cells (*p<0.05. Ile119Met, circles; wild-type, squares)
1064 Diabetologia (2011) 54:1057–1065In summary, we provide evidence that the Ile119Met
INSR mutation is a loss-of-function mutation that causes
autosomal recessive extreme insulin resistance, with a
strong founder effect in the region of the Horn of Africa.
We thus suggest that any patient of Yemeni or Somali
origin who presents with extreme insulin resistance should
be screened first for this allele. The Ile119Met insulin
receptor shows normal steady state insulin binding and
autophosphorylation in response to insulin, but mildly
perturbed proreceptor processing and insulin dissociation,
particularly in acidic conditions.
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